Actively Recruiting
Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma
Led by Sun Yat-sen University · Updated on 2026-04-08
200
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This prospective observational study evaluates serial circulating tumor DNA (ctDNA) and molecular residual disease (MRD) monitoring in patients with neuroblastoma. The study aims to characterize baseline genomic alterations, assess ctDNA detectability and dynamic changes during treatment and follow-up, compare tumor-informed personalized MRD assays with fixed-panel assays, and determine the clinical utility of ctDNA/MRD for treatment response assessment, molecular remission evaluation, relapse surveillance, and early detection of disease progression.
CONDITIONS
Official Title
Serial ctDNA and Molecular Residual Disease Monitoring in Neuroblastoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with histologically or clinically confirmed neuroblastoma according to institutional or protocol-defined diagnostic criteria.
- Newly diagnosed, relapsed, refractory, or progressive neuroblastoma eligible for serial biospecimen collection during routine clinical care.
- Availability of peripheral blood samples for ctDNA/MRD analysis at baseline and/or longitudinal follow-up time points.
- Availability of clinical data required for molecular-clinical correlation analyses, including response and outcome assessment.
- Availability of tumor tissue and matched control samples for tumor-informed assay development, if applicable and feasible.
- Written informed consent from a parent or legal guardian, and assent from the participant when applicable.
You will not qualify if you...
- Inability to provide protocol-required blood samples for ctDNA/MRD testing.
- Insufficient clinical information for protocol-defined response or outcome analyses.
- Poor-quality or insufficient biospecimens that preclude molecular analysis, when molecular testing is a required component of the study dataset.
- Any condition that, in the opinion of the investigator, would make study participation inappropriate.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510080
Actively Recruiting
Research Team
Y
Yizhuo Zhang, Doctor of Haematology
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here